IDWeek 2018 — We are not on track to end AIDS


  • Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Melanie Thompson of AIDS Research Consortium of Atlanta presented what's hot in HIV clinical science.
  • People with HIV can live a near-normal lifespan free of AIDS with early and continuous antiretroviral therapy (ART).
  • We know how to prevent HIV infections but are not on track to end AIDS.

Why this matters

  • Some populations are being left behind.
  • Funding declining while care/treatment needs increase.
  • Fewer than half of people with HIV are virally suppressed.

Key highlights

  • Health disparities, structural barriers remain key issues.
  • Case numbers hit records lows in some places (e.g., San Francisco), but disparity gap widens.
  • Black men living with HIV have highest mortality rates; e.g., in Atlanta, 80% of newly diagnosed are black men.
    • Thompson says, “We are not going to end anything until we stop leaving people of color behind.”
  • Treatment is prevention, she says, if there is zero transmission and virus is durably suppressed.
    • She cites PARTNER 2 study, where transmission was 0 from main partner, despite high rates of condom-free sex.
    • Pre-exposure prophylaxis (PrEP) works, but the problem is that among population indicated for PrEP, only 8% were prescribed it in 2015 (mostly white men; only 1% of black people who needed it got it).
  • Despite new drugs approved or on the horizon, costs remain unclear.
  • New looming problems include:
    • Neural tube defect signal detected in Botswana with dolutegravir.
    • Other potential developmental neurological signals with in utero exposure to efavirenz. 
    • Other considerations are structural barriers to, e.g., rapid ART start, which can cut time to viral suppression in half.
    • People with HIV are aging, so comorbidities are increasing; e.g., HIV doubles cardiovascular disease risk.
  • Without change, says Thompson, another 55,000 people with have a new HIV infection by 2030.
  • Implementing 95-95-95 targets would drop that to 19,000/years; adding in PrEP would decrease to 14,000.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit